As more people turn to medications like Ozempic or Wegovy for weight loss, a new wave of stories is circulating online, some claiming changes to vulvas, penises, and sexual function. Terms like “Ozempic vulva” have begun appearing on social media, raising many questions.
Some have begun referring to an “Ozempic vulva,” or, more broadly, what I call “GLP-1 genitals,” because there may be groups of GLP-1* users noticing changes they are not always eager to report.
For women, the so-far reported changes include sagging or less full vulvar tissue, vaginal dryness, and sensations consistent with weaker pelvic-floor muscles. These descriptions are currently anecdotal, but they are physiologically plausible, largely due to rapid fat loss and reductions in overall muscle mass.
Regarding men, some individuals with male genitals are reporting not concern but rather a perceived “augmentation,” which is most likely due to increased visibility of the penile shaft after significant reduction of suprapubic fat. However, what is less often discussed are potential issues similar to those described by women, particularly around pelvic-floor strength, given that these muscles contribute to erectile firmness, ejaculation, and overall sexual function with worse endurance and weaker ejaculation.
As reported in the articles listed below, the mechanism of GLP-1 medications can contribute to generalized lean mass loss, including skeletal muscle, due to significant caloric deficit. In addition, the fat pads that normally cushion and support vulvar structures may decrease in size with rapid weight loss, leaving the vulva more exposed and, in some cases, more prone to friction, irritation, or discomfort. Some clinicians emphasize that these changes are not inherent to GLP-1 medications themselves but are consistent with rapid, medically induced weight loss of any kind, such as that seen after bariatric surgery or very-low-calorie diets. Still, taken together, these emerging observations raise important questions about how the body responds when weight reduction occurs quickly, and what patients should understand before beginning GLP-1 therapy, particularly regarding potential genital, pelvic, and sexual health effects. There are also reports suggesting possible changes in skin elasticity, perceived skin aging, and aspects of sexual function, though these too are early and require systematic study (more below).
Have you encountered any side-effects while using GLP-1s? Feel free to share below if you are comfortable doing so.
*Glucagon-Like Peptide-1, which is a natural hormone your body produces, which plays a key role in regulating blood sugar and appetite.
Sources—Read More:
Catalfamo, L., De Ponte, F. S., & De Rinaldis, D. (2025). “Ozempic Face”: An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)—Our Experience. Journal of Clinical Medicine, 14(15), 5269. https://doi.org/10.3390/jcm14155269
Mohammed GF, Al-Dhubaibi MS, Bahaj SS, Mohammed RM. Tirzepatide Affect Sexual Function in Women: Case Report. Clinical Medicine Insights: Case Reports. 2025;18. doi:10.1177/11795476251347753
Paschou, I.A., Sali, E., Paschou, S.A. et al. GLP-1RA and the possible skin aging. Endocrine 89, 680–685 (2025). https://doi.org/10.1007/s12020-025-04293-w
Prado, Carla M et al. Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes & Endocrinology, Volume 12, Issue 11, 785 – 787 https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00272-9/abstract
Stokes, V. (2025, August 23). What is ‘Ozempic vulva’ and is it a real side effect of GLP-1 drugs? Healthline. https://www.healthline.com/health-news/ozempic-vulva-side-effect-glp-1-drugs
public-journalism.news 